Topic: soft tissue sarcomas

Eli Lilly headquarters

8. Eli Lilly

Eli Lilly spent nearly a quarter of its income on R&D last year, putting it near the top of its peers in percentage terms, and saw some of that spend pay off—overall, however, last year was a mixed bag for the company’s research.
FDA sign

18. Lartruvo

En route to its accelerated approval in October, Eli Lilly’s olaratumab seemed to rack up every possible shortcut from the FDA—fast-track and breakthrough therapy designations as well as priority review and orphan drug designation.